Legislation on biotechnology in the Nordic countries updated for 2019

Each year, the Nordic Committee on Bioethics publishes an updated overview of legislation within biotechnology in the Nordic countries. Given the clear need for such overviews, the committee decided to update the tables to reflect recent legal amendments.

The aim of this report is to give the reader information on the current status in the different countries and a chance to compare the legal situations. In this edition we have added two new topics; One is NIPT (Non-Invasive Prenatal Test). The other is Direct-to-consumer genetic testing (DTC-GT). DTC-GT was introduced to the private market without any formal procedures and remains to a large degree unregulated. As part of the national health care systems, the use of NIPT requires a formal process of approval, carried out either by the government or hospital. But also NIPT is offered as a private service.

You can download or order the report here
And find links to previous NCBio publications here



The report covers the following areas of legislation:
1. Assisted reproduction
2. Preimplantation genetic diagnosis (PGD)
3. Preimplantation genetic screening (PGS)
4. Abortion
5. Prenatal diagnosis and/or screening (national programmes)
6. Organ and tissue transplantation
7. Embryo research
8. Cloning
9. Clinical research on humans
10. Human biobanks
11. Ethical committees
12. Genetic testing
13. Advanced therapy medicinal products (ATMP, i.e. gene therapy, somatic cell therapy, stem cell therapy, tissue engineering)
14. Genetically modified organisms
15. Animal experimentation
16. Legal status of the Council of Europe Biomedicine Convention and its additional protocols